Endothelial damage after treatment with low-molecular weight heparins - A morphological study

Scandinavian Cardiovascular Journal

Volumn 37, Issue 1, 2003, Pages 30-33

  Kinhult, Sara ^a   Eskilsson, Jan ^a   Albertsson, Maria ^a   Cwikiel, Magdalena ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Endothelium; Low molecular weight heparin; Scanning electron microscopy

Indexed keywords

DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; SODIUM CHLORIDE; TINZAPARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTERY ENDOTHELIUM; ARTICLE; BLOOD VESSEL WALL; CELL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; ENDOTHELIUM CELL; ENDOTHELIUM LESION; ISCHEMIC HEART DISEASE; LONG TERM CARE; MALE; MEMBRANE DAMAGE; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPE; SUBENDOTHELIUM; THROMBOCYTE ADHESION;

ANIMALS; ANTICOAGULANTS; ARTERIES; DALTEPARIN; ENDOTHELIUM, VASCULAR; ENOXAPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; MALE; MICROSCOPY, ELECTRON, SCANNING; RABBITS; TIME FACTORS;

EID: 0037649979     PISSN: 14017431     EISSN: None     Source Type: Journal    
DOI: 10.1080/14017430310007009     Document Type: Article

References (15)

1. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79(1): 1-17.
2. Fragmin and Fast Revascularisation during InStability in Coronary artery disease (FRISC II) Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354: 701-707.
3. Wallentin L. Low-molecular-weight heparin as a bridge to timely revascularisation in unstable coronary artery disease - an update of the Fragmin during instability in coronary artery disease II trial. Haemostasis 2000; 30 Suppl 2: 108-113.
4. Merlini P, Bauer K, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-68.
5. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447-452.
6. Antman E, McCabe CH, Premmereur J, et al. Enoxaparin for the acute and chronic management of unstable angina/non-Q-wave myocardial infarction: Results from the TIMI 11B study. Circulation 1999; 100: 1593-1601.
7. Kinhult S, Albertsson M, Eskilsson J, Cwikiel M, Antithrombotic treatment in protection against thrombogenic effects of 5-fluorouracil on vascular endothelium: A scanning microscopy evaluation. Scanning 2001; 23: 1-8.
8. Centrala djurförsöksnämnden. Provisions and general recommendations relating to the use of animal for scientific purposes. Department of Agriculture, Stockholm, Sweden 1999.
9. Wieslander JB. The appearance of normal vascular wall and endothelium in small arteries. Microsurgery 1987; 8: 173-179.
10. Wieslander JB, Stjernquist U. The influence of non-ionic contrast media on the endothelium of small arteries. Acta Radiol Suppl 1987; 370: 73-77.
11. Mattson JC, Peterson DM, McCarron S, Stathopoulos N. The Bernard-Soulier platelet: II. A comparative study of changes in platelet morphology and cytoskeletal architecture following contact activation. Scanning Electron Microsc 1984; IV: 1941-1950.
12. Cwikiel M, Albertsson M, Eskilsson J, Stjernqvist U, Wieslander JB, The appearance of endothelium in small arteries after treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits. Scanning Microsc 1996; 10(3): 805-820.
13. Cwikiel M, Eskilsson J, Albertsson M, Stavenow L, The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in culture. Ann Oncol 1996; 7: 731-737.
14. Upchurch GR Jr, Welch GN, Freedman JE, et al. High-dose heparin decreases nitric oxide production by cultured bovine endothelial cells. Circulation 1997; 95: 2115-2121.
15. Bachetti T, Pasini E, Clini E, Cremona G, Ferrari R. High-dose heparin impairs nitric oxide pathway and vasomotion in rats. Circulation 1999; 99: 2861-2863.